Pharming Group NV (PHAR), a Dutch biopharmaceutical company, said on Tuesday that its Board has nominated Fabrice Chouraqui to become its Chief Executive Officer to succeed Sijmen de Vries.
The company will nominate Chouraqui for the appointment as CEO for a term of four years at an upcoming extraordinary general meeting of shareholders.
Upon the appointment, Vries will resign from the Board. However, he will remain as a strategic advisor to the new CEO until December 31.
For comments and feedback: editorial@rttnews.com